LOS ANGELES–(COMMERCIAL THREAD) – Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors from Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ : NVAX) for violating securities laws.
The investigation focuses on whether the Company has made false and / or misleading statements and / or failed to disclose relevant information to investors. Novavax is the subject of an article published by Politics on October 19, 2021, titled: “They Rushed the Process: Vaccine Maker’s Woes Hinder Global Immunization Campaign.” According to the article, “Manufacturing problems jeopardize billions of doses destined for poor and middle-income countries.” The article continues, “Although Novavax has recently attested to some of its analysis and testing problems … the company’s problems are more of a concern than previously thought, according to two of those with direct knowledge of the topic.” Based on this news, the Novavax share traded heavily on October 20, 2021.
If you are a shareholder who has suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com or by email at [email protected]
The class in this case has not yet been certified, and until certification occurs, you are not represented by legal counsel. If you choose to do nothing, you can remain an absent member of the group.
The Schall law firm represents investors around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered an attorney’s advertisement in certain jurisdictions under applicable law and rules of professional conduct.